A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome

References

• Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–15. doi:10.3748/wjg.v20.i22.6759.
   PubMed Web of Science ®Google Scholar
• Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35. doi:10.1186/s12955-017-0611-2
   PubMed Web of Science ®Google Scholar
• Ford AC, Lacy BE, Talley NJ, Longo DL. Irritable bowel syndrome. N Engl J Med. 2017;376(26):2566–2578. doi:10.1056/NEJMra1607547
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21.e4. doi:10.1016/j.cgh.2012.02.029
   PubMed Web of Science ®Google Scholar
• Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S. et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021;160(1):99–114. e3. doi:10.1053/j.gastro.2020.04.014
   PubMed Web of Science ®Google Scholar
• Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology. 2016;150(6):1393–407. e5. doi:10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010;7(10):565–581. doi:10.1038/nrgastro.2010.137
   PubMed Web of Science ®Google Scholar
• Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68–72. quiz 3. doi:10.1016/j.cgh.2008.07.008
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S. et al. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastro Hepat. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66
   PubMed Web of Science ®Google Scholar
• Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. Nutrients. 2020;12(2):12. doi:10.3390/nu12020363
   Web of Science ®Google Scholar
• Wang Y, Chen N, Niu F, Li Y, Guo K, Shang X, E F, Yang C, Yang K, Li X. et al. Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs. Int J Colorectal Dis. 2022;37(11):2263–2276. doi:10.1007/s00384-022-04261-0
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. doi:10.1186/s12876-016-0470-z
   PubMedGoogle Scholar
• Konstantis G, Efstathiou S, Pourzitaki C, Kitsikidou E, Germanidis G, Chourdakis M. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria. Clin Nutr. 2023;42(5):800–809. doi:10.1016/j.clnu.2023.03.019
   PubMed Web of Science ®Google Scholar
• van der Geest AM, Schukking I, Brummer RJM, van de Burgwal LHM, Larsen OFA. Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Benef Microbes. 2022;13(3):183–194. doi:10.3920/BM2021.0123
   PubMed Web of Science ®Google Scholar
• Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23(1):37–46. doi:10.1017/S0954422410000090
   PubMed Web of Science ®Google Scholar
• Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658–666. doi:10.1016/S2468-1253(20)30056-X
   PubMed Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. doi:10.1046/j.1365-2036.1997.142318000.x
   PubMed Web of Science ®Google Scholar
• Spiegel B, Bolus R, Harris LA, Lucak S, Naliboff B, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K. et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009;30(11–12):1159–1170. doi:10.1111/j.1365-2036.2009.04144.x
   PubMed Web of Science ®Google Scholar
• EMA. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. 2014
   Google Scholar
• FDA. Guidance document. Irritable bowel syndrome - clinical evaluation of products for treatment. 2021
   Google Scholar
• Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400–411. doi:10.1023/A:1018831127942
   PubMed Web of Science ®Google Scholar
• Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Dalton CB, Leserman J, Patrick DL, Bangdiwala SI. et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;102(7):1442–1453. doi:10.1111/j.1572-0241.2007.01283.x
   PubMed Web of Science ®Google Scholar
• Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307–312. doi:10.1111/j.2002.384.doc.x
   PubMed Web of Science ®Google Scholar
• Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301–308. doi:10.1016/j.jclinepi.2011.07.011
   PubMed Web of Science ®Google Scholar
• Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287–291. doi:10.1002/pst.185
   Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EMM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–1590. doi:10.1111/j.1572-0241.2006.00734.x
   PubMed Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551. doi:10.1053/j.gastro.2004.11.050
   PubMed Web of Science ®Google Scholar
• Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18(1):71. doi:10.1186/s12876-018-0788-9
   PubMedGoogle Scholar
• Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B. The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study. Nutrients. 2021;13(3):756. doi:10.3390/nu13030756
   PubMed Web of Science ®Google Scholar
• Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung W-S. et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2012;46(3):220–227. doi:10.1097/MCG.0b013e31823712b1
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, et al. Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with Bifidobacterium Longum ES1 for 8 or 12 weeks: a preliminary report. J Clin Med. 2020 Jul 23;9(8):2353. doi:10.3390/jcm9082353
   PubMed Web of Science ®Google Scholar
• Rahman MM, Mahadeva S, Ghoshal UC Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: a review. World J Gastroenterol. 2017 Oct 10;23(37):6788.
   PubMed Web of Science ®Google Scholar
• Sarkar A, Mandal S. Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action. Microbiol Res. 2016;192:159–171. doi:10.1016/j.micres.2016.07.001
   PubMed Web of Science ®Google Scholar
• Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, Shuai O, Zhou G, Xie Y, Wu Q. et al. Prebiotic effect of Fructooligosaccharides from Morinda officinalis on Alzheimer’s Disease in rodent models by targeting the microbiota-gut-brain axis. Front Aging Neurosci. 2017;9:403. doi:10.3389/fnagi.2017.00403
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients. 2021;13(6):2099. doi:10.3390/nu13062099
   PubMed Web of Science ®Google Scholar